The announcement made at second edition of Africa Health Excon

Grifols Egypt for Plasma Derivatives, a joint-venture company between the National Services Projects Organization and Grifols, a global healthcare company, today announced that its first plasma-derived-medicines, made from Egyptian donations, are available to administer to Egyptian patients.
Grifols Egypt made its announcement during the second edition of the Africa Health ExCon, currently underway in Cairo.

Hospitals in Egypt will soon receive large quantities of Grifols Egypt albumin, a critical plasma medicine used in major surgery and to treat trauma and severe burns. The first shipment begins what will be a constant supply of the company’s plasma therapies that will include immunoglobulins for immunodeficiencies and blood-clotting factors to manage bleeding disorders.

Over time it’s expected that Egypt will achieve self-sufficiency in these vital treatments, greatly enhancing the Egyptian healthcare system.
Grifols Egypt medicines are currently manufactured in a Grifols plant in Barcelona, Spain, until a new manufacturing site is completed and operational in the Medical City in the New Administrative Capital. It will also include testing facilities and storage centers. 

Plasma donations come from a growing Grifols Egypt network of donation centers. Of the 20 centers planned, six are already up and running, with another four expected to be open by the end of this year and 10 more in 2024.

All Grifols Egypt operations adhere to the highest international quality and safety standards.